Emergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK-positive metastatic non-small cell lung cancer: A case report. [PDF]
Oncol LettSimon A +9 more
europepmc +1 more source
Cancer Science, EarlyView.This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda +9 more
wiley +1 more source
Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre. [PDF]
Lung Cancer ManagFujita K +9 more
europepmc +1 more source
Cancer Science, EarlyView.Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang +6 more
wiley +1 more source
Case Report: Single-cell transcriptomic profiling of a pediatric ALK-negative gastric inflammatory myofibroblastic tumor. [PDF]
Front ImmunolNong J, Li W, Shi B.
europepmc +1 more source
Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer
Cancer Science, EarlyView.This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao +5 more
wiley +1 more source
Cancer Science, EarlyView.Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui +15 more
wiley +1 more source
Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN
Cancer Science, EarlyView.In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi +16 more
wiley +1 more source
Primary Renal Mesenchymal Tumors: A Study from North India, Emphasizing Rare Entities and Molecular Profiles. [PDF]
J Kidney Cancer VHLYadav A +4 more
europepmc +1 more source
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto +121 more
wiley +1 more source